Skip to main content

Table 2 Pulmonary function tests and mRSS at baseline and 6 months, and HRCT outcome in 26 systemic sclerosis patients treated with imatinib

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Patient (PIN) FVC (l) T0 FVC (l) T6 ΔFVC (T0 – T6) (%) DLco (ml/mmHg/minute) T0 DLco (ml/mmHg/minute) T6 ΔDLco (T0 – T6) (%) HRCTaT0 HRCTaT6 HRCT (evaluation at T6) mRSS T0 mRSS T6 ΔmRSS (T0 – T6) (%) Months from the end of CYC/cumulative dose of CYC/other therapies
86 3.23 3.84 −5.88 8.45 10.78 27.57 19/18 4/18 Improved 4 3 −25 21/10 g/Aza
509 3.36 2.71 –19.3 10.64 14.05 32.05 6/2 4/2 Improved 24 31 29.16 48/7.5 g/Mtx
642 1.53 1.57 2.61 8 10 25 9/9 6/9 Improved 5 6 20 11/70 g
649 1.79 1.83 2.23 8.44 9.54 19.62 6/8 7/9 Unchanged 3 3 0 3/10 g/CyA
18 2.35 2,31 –1.7 18.99 19.92 4.9 6/8 3/8 Improved 0 0 0 42/13.5 g/Aza
115 2.69 2.45 –8.92 16.1 17 6.83 4/2 4/2 Unchanged 20 20 0 12/18 g/Aza, Rtx
205 1.52 1.43 –5.92 4.9 5 2.04 6/20 0/20 Improved 5 6 29.16 22/21 g
214 3.16 3,16 0 12.9 14 8.53 10/8 1/9 Improved 29 25 −13.79 9/6 g
219 1.97 1.83 −7.1 8.5 8.1 −4,7 20/20 20/20 Unchanged 10 16 60 36/6 g/Aza
297 2,19 2.24 2.28 7.2 7.49 4.02 13/7 12/7 Unchanged 22 17 −22.72 20/6 g
304 2.41 2.56 6.22 15.1 14.4 −4.63 12/3 11/3 Unchanged 11 9 −18.18 3/6 g
371 3.14 3.56 13.37 17.8 19.7 10.67 6/8 0/8 Improved 6 6 0 4/8.2 g
432 1.77 1.82 2.82 5.31 5.77 8.66 14/17 13/17 Unchanged 9 9 0 8/9 g
482 1.55 1.43 −7.74 7.68 7.39 −3.78 11/14 1/14 Improved 5 4 −20 7/9 g
522 3.20 3.08 −3.75 13.18 13.2 0.15 12/6 4/5 Improved 28 31 10.71 10/9 g
586 2.21 2.42 9.5 8.6 9.1 5.81 6/12 5/12 Unchanged 28 30 7.14 3/6 g
696 3.29 3.27 −0.6 14.5 14.19 2.76 11/6 7/7 Improved 8 10 25 15/7,2 g
763 3.81 3.75 −1.5 16.4 16.9 3.05 14/13 8/13 Improved 17 20 17.64 15/6 g/Rtx
801 2.09 2.13 1.9 10.5 11.5 9.52 16/12 8/13 Improved 15 11 26.66 3/7,2 g
144 3.56 3.57 0.28 9.65 6.16 –36.16 9/14 4/16 Worsened 15 15 0 6/10 g
358 2.24 1.81 –19.2 8.30 7.6 –8.63 8/14 4/14 Improved 14 24 71.42 12/38 g/Aza
459 2.44 1.97 –19.26 10.4 9.9 –4.81 14/20 14/20 Unchanged 25 27 8 15/9 g
534 3.26 3.01 −7.6 15.12 14.93 −1.26 5/4 10/12 Worsened 0 0 0 28/10 g/Aza
552 1.95 1.95 0 8.98 7.86 −11.36 18/18 20/20 Worsened 28 31 10.71 8/20 g/Aza, MMF
706 1.86 1.7 −8.6 6.21 3.55 −42.83 6/20 6/20 Unchanged 10 10 0 7/6 g/Aza
789 2.04 2.12 3.9 10.7 10.4 −2.8 10/4 10/10 Worsened 7 10 42.85 21/7.2 g
  1. Bold data indicate that patients responders: Roman data indicate that patients stabilized; italic data indicate that patients worsened. Aza, azathioprine; CyA, cyclosporine A; CYC, cyclophosphamide; DLco, diffusion lung capacity of carbon monoxide; FVC, forced vital capacity; HRCT, high-resolution computed tomography; Mtx, methotrexate; MMF, mycofenomycophenolate mophetil; mRSS, modified Rodnan skin score; Rtx, rituximab; T0, baseline; T6, 6-month visit; Δ = (T6/T0 × 100) – 100. aNumber of segments with ground-glass/honeycombing.